

# TITLE: NEW METHOD FOR EVALUATING DRUG RESPONSE AND NEW TREATMENT STRATEGIES IN OVARIAN CANCER

## FIELD OF INTEREST

Biotechnology, Pharma (Oncology, Personalised medicine)

## CLINICAL NEED

Ovarian cancer is the gynecological disease that causes the most deaths in developed countries. With an incidence of 204,000 cases per year, it causes 125,000 deaths worldwide. Mortality at 5 years is around 70-80%, being in most cases due to the progression and metastasis of the tumor.

The surgical and pharmacological treatment suitable for each type of tumor depends on its extension and its risk of progression, as in the rest of tumors; but in ovarian cancer the surgical decision should be as conservative as possible, in order to avoid the loss of fertility in patients.

Although most patients respond to drug treatment, many patients develop resistance to platinum-based antitumor compounds, resulting in rapid progression of the disease. The exact mechanism by which ovarian cancer cells become resistant to treatment is currently unknown.

## DESCRIPTION OF THE INVENTION

New method to determine the response to ovarian cancer therapy based on platinum and to design a new personalized therapy upon patient's genetic profile (miRNAs).

## TECHNOLOGY KEYWORDS

CDDP response, DNA methylation, miRNAs, cancer

## IPR STATUS

Patent application number: P201530997.

Applicants: FIBHULP, CSIC, UAM, IIS-FJD.

## TYPE AND ROLE OF PARTNER

Looking for commercial partners interested in licensing.

---

## Contact details:

Innovation Unit

e-mail: [irene.ruano@fjd.es](mailto:irene.ruano@fjd.es)

Phone number: 0034-915504800 Ext.3455